MENU

Primary Hyperaldosteronism: From A to Z

Sponsored by: DiaSorin
Speaker
  • Assistant Professor of Medicine at Harvard Medical School and Associate Physician at Brigham and Women's Hospital, Division of Endocrinology
    Biography
      Dr. Williams is an Assistant Professor of Medicine at Harvard Medical School and Associate Physician at Brigham and Women's Hospital, Division of Endocrinology, Diabetes, and Hypertension.  He has dedicated his research efforts to unravelling the intricate relationship between genetics and environment with respect to individual susceptibility to cardiometabolic disease.  He has over 40 original publications describing the physiologic and pathologic interplay of renin-angiotensin-aldosterone system activity and dietary salt intake in hypertension, insulin resistance, heart disease, and obesity.  His work is funded through National Institutes of Health, industry, and private foundation support.
       
      Dr. Williams is an active program developer, course director, and mentor for the Harvard Medical School's Scholars in Clinical Research Program, which is a Master's degree granting program designed to train the upcoming generation of patient-oriented physician scientists.  He is also an Associate Editor of the journal Metabolism, and serves on the Board of Directors for the Association for Patient-oriented Research and for the Association for Clinical and Translational Science.

    Abstract

    The prevalence of primary hyperaldosteronism among general and resistant hypertensive populations ranges from 5-20%.  It is considered a secondary form of hypertension caused by inappropriate secretion of aldosterone and activation of the mineralocorticoid receptor.  As such, it is a highly treatable and potentially curable form of hypertension.  This webinar will review the prevalence, pathophysiology, screening and diagnostic studies, and treatment options for patients with primary hyperaldosteronism so that the Practitioner can accurately screen and identify cases.

    Learning objectives:

    1.  Understand the prevalence, pathophysiology and diagnostic studies for patients with primary hyperaldosteronism.
     
    2.  Be able to identify screening and treatment options for patients with primary hyperaldoseronism.
     
     


    Show Resources
    You May Also Like
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    FEB 19, 2020 11:00 AM PST
    C.E. CREDITS
    FEB 19, 2020 11:00 AM PST
    DATE: February 19, 2020TIME: 11:00am PST, 2:00pm EST...
    JUN 17, 2020 1:30 PM PDT
    C.E. CREDITS
    JUN 17, 2020 1:30 PM PDT
    Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    MAR 11, 2020 6:00 AM PDT
    C.E. CREDITS
    MAR 11, 2020 6:00 AM PDT
    The locomotion of humans and other animals requires a seamless flow of information from sensory modalities all the way to the motor periphery. As such, locomotion is an excellent system for...
    Loading Comments...
    Show Resources
    Attendees
    • See more